Best Hospitals for Bladder Cancer Treatment in Delhi NCR, India

Bladder cancer arises from the urothelial lining of the bladder wall and accounts for approximately 573,000 new diagnoses globally each year, making it the tenth most common malignancy worldwide. The vast majority of cases—roughly 90%—are urothelial (transitional cell) carcinomas, with the remainder comprising squamous cell carcinomas, adenocarcinomas, and rarer variants such as small-cell or sarcomatoid tumors. Risk factors include cigarette smoking (attributable to 50–65% of male cases), occupational exposure to aromatic amines and polycyclic aromatic hydrocarbons, chronic Schistosoma haematobium infection, pelvic radiation history, and cyclophosphamide use. Germline alterations in FGFR3, TP53, RB1, and ERCC2 influence both prognosis and therapeutic sensitivity.

• Confirmed urothelial carcinoma or variant histology on biopsy (TURBT specimen with muscularis propria in sample mandatory for accurate staging)
• NMIBC (Ta, T1, CIS) candidates: patients with recurrent or high-grade tumors, BCG-naive or BCG-unresponsive disease, or those failing prior intravesical chemotherapy
• MIBC (T2–T4a, N0–N2, M0) candidates: medically operable patients with ECOG performance status 0–2 and adequate renal function (GFR ≥ 45–60 mL/min) for neoadjuvant cisplatin eligibility
• Bladder-preservation (trimodality) candidates: solitary T2–T3a tumor, absence of extensive CIS, complete/near-complete TURBT achievable, no hydronephrosis, adequate bladder capacity and function
• Metastatic or recurrent disease candidates: systemic therapy with gemcitabine + cisplatin or carboplatin (cisplatin-ineligible); atezolizumab or pembrolizumab for PD-L1-positive cisplatin-ineligible patients; erdafitinib for FGFR3/2-altered tumors post-platinum; enfortumab vedotin ± pembrolizumab for subsequent lines

Required Diagnostic Workup Before Travel:

• Cystoscopy with biopsy (TURBT pathology report with grade, stage, and presence of muscularis propria)
• CT Urography (CT scan of chest, abdomen, and pelvis with contrast) for locoregional and metastatic staging
• PET-CT scan (18F-FDG) for equivocal lymph node findings or suspected distant metastasis in MIBC
• MRI of pelvis (mpMRI) for accurate T-staging of MIBC and neobladder surgical planning
• Complete blood count, serum creatinine, GFR (24-hour urine or CKD-EPI calculation), liver function tests, serum electrolytes
• +3 more

TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) — Standard & Enhanced:

TURBT is the cornerstone procedure for diagnosis, staging, and definitive treatment of NMIBC. The surgeon uses a rigid resectoscope passed transurethrally under spinal or general anesthesia to resect the tumor en bloc or piecemeal, including the underlying detrusor muscle. Enhanced modalities significantly improve complete resection rates and reduce recurrence:

• Blue-Light Cystoscopy (Hexvix/Cysview hexaminolevulinate): increases detection of flat CIS lesions by 30–40% compared to white-light cystoscopy, reducing residual tumor at re-TURBT
• Narrow-Band Imaging (NBI): digital contrast enhancement improving papillary and CIS detection without photosensitizing agents
• En Bloc TURBT (laser-assisted or standard): preserves lamina propria and muscularis propria architecture, improving staging accuracy and pathological quality; performed with Holmium:YAG or Thulium fiber laser
• Second-Look TURBT: mandatory 4–6 weeks after initial resection for all T1 high-grade and T1 with no muscularis propria in specimen; reduces understaging by 20–30%

Intravesical THERAPY:

PHASE 1 — PRE-ARRIVAL PREPARATION (4–8 weeks before travel):

• GAF Healthcare case manager reviews all existing medical records, biopsy pathology, imaging (CT urography, PET-CT, MRI pelvis), molecular profiling results, and blood work
• Virtual consultation arranged with assigned oncologist and urologic surgeon at partner hospital within 48–72 hours
• Multidisciplinary tumor board (urology, medical oncology, radiation oncology, pathology) reviews case and confirms treatment plan
• e-Medical Visa (India) or UAE tourist/medical visa application supported by GAF team with hospital invitation letter
• Insurance pre-authorization documentation prepared
• Travel and accommodation logistics confirmed for patient and companion

PHASE 2 — ARRIVAL & WORKUP (Days 1–4):